We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.
- Authors
Martins, L R; Lúcio, P; Melão, A; Antunes, I; Cardoso, B A; Stansfield, R; Bertilaccio, M T S; Ghia, P; Drygin, D; Silva, M G; Barata, J T
- Abstract
The article presents a study which aims to evaluate whether CK2-specific inhibitor CX-4945 may be a valid therapeutic option against chronic lymphocytic leukemia (CLL). It notes the correlation of the in vitro effects of the inhibitor with several clinical parameters to further evaluate the putative therapeutic impact of CX-4945 in CLL. It also reveals the significant improvement when CX-4945 was used in combination with fludarabine in agreement with their synergistic effect observed in vitro.
- Subjects
PROTEIN kinase inhibitors; CHRONIC lymphocytic leukemia treatment; CLINICAL medicine; FLUDARABINE; IN vitro studies
- Publication
Leukemia (08876924), 2014, Vol 28, Issue 1, p179
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/leu.2013.232